SNGX - Soligenix inks supply and distribution deal for SGX301 companion light device in cancer

Soligenix (SNGX) perks 8% premarket after signing an exclusive Supply, Distribution and Services Agreement with Daavlin.Pursuant to the Agreement, Daavlin will exclusively manufacture the proprietary light device for use with SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma ((CTCL)).Upon FDA approval, Soligenix will promote SGX301 and the companion light device, and facilitate the direct purchase of the device from Daavlin and latter will distribute and sell the SGX301 light device to Soligenix, physicians and patients.CTCL is a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.

For further details see:

Soligenix inks supply and distribution deal for SGX301 companion light device in cancer